Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ADCY1 | Q08828 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062469 | 0.86 | NOTUM (0.55) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL21776999 | 0.80 | NOTUM (0.56) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL762899 | 0.79 | NPC1 (0.65) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL8429484 | 0.79 | NOTUM (0.49) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL22996209 | 0.79 | KDM4E (0.66) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL27721644 | 0.78 | NPC1 (0.70) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17335667 | 0.77 | POLB (0.55) | NPC1RAB9ASMN1; SMN2MAPTADCY1 | |
| SCHEMBL22996164 | 0.76 | ALDH1A1 (0.42) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12171111 | 0.76 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2MAPTADCY1 | |
| SCHEMBL21336118 | 0.75 | HPGD (0.64) | NOTUMNPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | SAINT LOUIS UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210024489-A1 | TREATMENT AND PREVENTION OF NEUROPATHIC PAIN WITH P2Y14 ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-28 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | P2RY14, P2RY4, P2RY13 | NOTUM 3292/4885NPC1 2617/4885RAB9A 3104/4885 |
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885NPC1 51/4885RAB9A 2177/4885 |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | P2RY14, P2RY1, P2RY13 | NOTUM 4148/4885NPC1 3086/4885RAB9A 809/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885NPC1 7/4885RAB9A 1162/4885 |
| US-20210024489-A1 | TREATMENT AND PREVENTION OF NEUROPATHIC PAIN WITH P2Y14 ANTAGONISTS | P2RY14, P2RY4, P2RY13 | NOTUM 3292/4885NPC1 2617/4885RAB9A 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.